Literature DB >> 27000805

Significant clinical heterogeneity with similar ETFDH genotype in three Chinese patients with late-onset multiple acyl-CoA dehydrogenase deficiency.

Hong-Xia Fu1, Xin-Yi Liu1, Zhi-Qiang Wang1,2, Ming Jin1, Dan-Ni Wang1, Jun-Jie He1, Min-Ting Lin1, Ning Wang3,4.   

Abstract

Late-onset multiple acyl-CoA dehydrogenase deficiency (MADD) with electron transfer flavoprotein dehydrogenase (ETFDH) gene mutations is the most common lipid storage myopathy (LSM) in China. Its clinical features vary widely and pose a challenge for diagnosis. We presented the significant clinical heterogeneity among three Chinese late-onset MADD patients with similar ETFDH genotype by collecting clinical information, muscle histology, and genetic analysis. Three novel compound heterozygous variants of ETFDH gene were identified: c.892C > T (p.Pro298Ser), c.453delA (p.Glu152ArgfsTer15), and c.449_453delTAACA (p.Leu150Ter). Moreover, all patients carried a hotspot mutation c.250G > A (p.Ala84Thr). Western blot analysis of the patients' muscular tissue showed a significantly reduced ETFDH expression, and normal electron transfer flavoprotein A (ETFA) and electron transfer flavoprotein B (ETFB) expression. Two patients with similar genotypes (c.453delA and c.449_453delTAACA) presented a significant clinical heterogeneity. Among them, one exhibited muscle weakness and exercise intolerance as initial and major symptoms, and the other showed episodic recurrent gastrointestinal symptoms before a serious muscle weakness appeared in later life. The novel variants in ETFDH and the corresponding clinical features enrich the variant spectrum of late-onset MADD and provide a new insight into the genotype-phenotype relationship. Late-onset MADD should be included in differential diagnosis for adult myopathy along with chronic digestive disease.

Entities:  

Keywords:  Clinical heterogeneity; ETFDH; Late-onset multiple acyl-CoA dehydrogenase deficiency; Lipid storage myopathy; Variants

Mesh:

Substances:

Year:  2016        PMID: 27000805     DOI: 10.1007/s10072-016-2549-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  16 in total

1.  Structure of electron transfer flavoprotein-ubiquinone oxidoreductase and electron transfer to the mitochondrial ubiquinone pool.

Authors:  Jian Zhang; Frank E Frerman; Jung-Ja P Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-18       Impact factor: 11.205

2.  Molecular mechanisms of riboflavin responsiveness in patients with ETF-QO variations and multiple acyl-CoA dehydrogenation deficiency.

Authors:  Nanna Cornelius; Frank E Frerman; Thomas J Corydon; Johan Palmfeldt; Peter Bross; Niels Gregersen; Rikke K J Olsen
Journal:  Hum Mol Genet       Date:  2012-05-18       Impact factor: 6.150

3.  High frequency of ETFDH c.250G>A mutation in Taiwanese patients with late-onset lipid storage myopathy.

Authors:  M-Y Lan; M-H Fu; Y-F Liu; C-C Huang; Y-Y Chang; J-S Liu; C-H Peng; S-S Chen
Journal:  Clin Genet       Date:  2010-12       Impact factor: 4.438

Review 4.  Riboflavin-responsive multiple Acyl-CoA dehydrogenation deficiency in 13 cases, and a literature review in mainland Chinese patients.

Authors:  Min Zhu; Xuan Zhu; Xueliang Qi; Ding Weijiang; Yajing Yu; Hui Wan; Daojun Hong
Journal:  J Hum Genet       Date:  2014-02-13       Impact factor: 3.172

5.  Riboflavin-responsive lipid-storage myopathy caused by ETFDH gene mutations.

Authors:  Bing Wen; Tingjun Dai; Wei Li; Yuying Zhao; Shuping Liu; Chunhua Zhang; Honghao Li; Jinling Wu; Danian Li; Chuanzhu Yan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-09-15       Impact factor: 10.154

6.  Clinical and genetic analysis of lipid storage myopathies.

Authors:  Aya Ohkuma; Satoru Noguchi; Hideo Sugie; May Christine V Malicdan; Tokiko Fukuda; Kunio Shimazu; Luis Carlos López; Michio Hirano; Yukiko K Hayashi; Ikuya Nonaka; Ichizo Nishino
Journal:  Muscle Nerve       Date:  2009-03       Impact factor: 3.217

7.  Clear relationship between ETF/ETFDH genotype and phenotype in patients with multiple acyl-CoA dehydrogenation deficiency.

Authors:  Rikke K J Olsen; Brage S Andresen; Ernst Christensen; Peter Bross; Flemming Skovby; Niels Gregersen
Journal:  Hum Mutat       Date:  2003-07       Impact factor: 4.878

8.  Risk of sudden death and acute life-threatening events in patients with glutaric acidemia type II.

Authors:  Brad Angle; Barbara K Burton
Journal:  Mol Genet Metab       Date:  2007-10-31       Impact factor: 4.797

9.  ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency.

Authors:  Rikke K J Olsen; Simon E Olpin; Brage S Andresen; Zofia H Miedzybrodzka; Morteza Pourfarzam; Begoña Merinero; Frank E Frerman; Michael W Beresford; John C S Dean; Nanna Cornelius; Oluf Andersen; Anders Oldfors; Elisabeth Holme; Niels Gregersen; Douglass M Turnbull; Andrew A M Morris
Journal:  Brain       Date:  2007-06-20       Impact factor: 13.501

10.  So doctor, what exactly is wrong with my muscles? Glutaric aciduria type II presenting in a teenager.

Authors:  Michael W Beresford; Morteza Pourfarzam; Doug M Turnbull; Joyce E Davidson
Journal:  Neuromuscul Disord       Date:  2006-03-09       Impact factor: 4.296

View more
  10 in total

1.  Multiple Acyl-CoA Dehydrogenase Deficiency in an Infant.

Authors:  Xiao-Ming Hu; Li Li
Journal:  Indian J Pediatr       Date:  2018-08-20       Impact factor: 1.967

2.  Screening of multiple acyl-CoA dehydrogenase deficiency in newborns and follow-up of patients.

Authors:  Duo Zhou; Meiling Ye; Zhenzhen Hu; Yu Zhang; Lin Zhu; Rulai Yang; Xinwen Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2021-08-25

3.  Features and diagnostic value of body composition in patients with late-onset multiple acyl-CoA dehydrogenase deficiency.

Authors:  Wei Zheng; Xue Li; Shiyi Yang; Cheng Luo; Fei Xiao
Journal:  Acta Neurol Belg       Date:  2022-05-26       Impact factor: 2.471

4.  Myogenic Disease and Metabolic Acidosis: Consider Multiple Acyl-Coenzyme A Dehydrogenase Deficiency.

Authors:  A Dernoncourt; J Bouchereau; C Acquaviva-Bourdain; C Wicker; P De Lonlay; C Gourguechon; H Sevestre; P-E Merle; J Maizel; C Brault
Journal:  Case Rep Crit Care       Date:  2019-12-21

5.  Late-onset riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency (MADD): case reports and epidemiology of ETFDH gene mutations.

Authors:  Wei Chen; Youqiao Zhang; Yifeng Ni; Shaoyu Cai; Xin Zheng; Frank L Mastaglia; Jingshan Wu
Journal:  BMC Neurol       Date:  2019-12-18       Impact factor: 2.474

6.  A family with riboflavin-reactive lipid deposition myopathy caused by a novel compound heterozygous mutation in the electron transfer flavoprotein dehydrogenase gene.

Authors:  Yue Wu; Jingzhe Han; Yaye Wang; Jinru Zhang; Xueqin Song; Guang Ji
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

Review 7.  Lipid-storage myopathy with glycogen storage disease gene mutations mimicking polymyositis: a case report and review of the literature.

Authors:  Xiaoli Pan; Yuan Yuan; Bangcui Wu; Wendan Zheng; Mei Tian
Journal:  J Int Med Res       Date:  2022-03       Impact factor: 1.671

8.  Characterization of 31 Patients with Riboflavin-Responsive Multiple acyl-CoA Dehydrogenase Deficiency

Authors:  Jinru Zhang; Jingzhe Han; Yaye Wang; Yue Wu; Lixia Ma; Xueqin Song; Guang Ji
Journal:  Balkan Med J       Date:  2022-06-23       Impact factor: 3.570

9.  Hepatic Presentation of Late-Onset Multiple Acyl-CoA Dehydrogenase Deficiency (MADD): Case Report and Systematic Review.

Authors:  Maria Anna Siano; Claudia Mandato; Lucia Nazzaro; Gennaro Iannicelli; Gian Paolo Ciccarelli; Ferdinando Barretta; Cristina Mazzaccara; Margherita Ruoppolo; Giulia Frisso; Carlo Baldi; Salvatore Tartaglione; Francesco Di Salle; Daniela Melis; Pietro Vajro
Journal:  Front Pediatr       Date:  2021-05-10       Impact factor: 3.418

10.  Clinical characteristics and gene mutation analysis of an adult patient with ETFDH‑related multiple acyl‑CoA dehydrogenase deficiency.

Authors:  Chenyi Wang; Haihong Lv; Xia Xu; Yuping Ma; Qian Li
Journal:  Mol Med Rep       Date:  2020-09-18       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.